Number of the records: 1  

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

  1. 1.
    0092894 - ÚMG 2008 RIV GR eng J - Journal Article
    Reiniš, Milan - Šímová, Jana - Indrová, Marie - Bieblová, Jana - Bubeník, Jan
    CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
    [CpG oligonukleotidy jsou účinné při terapii minimální zbytkové nádorové choroby MHC I negativních myších nádorů asociovaných s HPV16 po chemoterapii nebo jejich chirurgickém dstranění.]
    International Journal of Oncology. Roč. 30, č. 5 (2007), s. 1247-1251. ISSN 1019-6439. E-ISSN 1791-2423
    R&D Projects: GA ČR GA301/04/0492; GA ČR GA301/06/0774
    EU Projects: European Commission(XE) 18933 - CLINIGENE
    Grant - others:Liga proti rakovině, Praha(CZ) XX
    Institutional research plan: CEZ:AV0Z50520514
    Keywords : HPV16 * minimal residual tumour disease * CpG oligonucleotides
    Subject RIV: EB - Genetics ; Molecular Biology
    Impact factor: 2.295, year: 2007
    Permanent Link: http://hdl.handle.net/11104/0153090
     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.